Dr Gerald Saldanha

Dr Gerald SaldanhaConsultant Histopathologist and Honorary Senior Lecturer

Room 322
Level 3
Robert Kilpatrick Clinical Sciences Building
Leicester Royal Infirmary

 

Tel: +44 (0)116 252 3228
Email: gss4@le.ac.uk

Personal details

  • MB ChB (Leicester)
  • PhD (Leicester)
  • FRCPath
  • MRCP (UK)

Academic distinctions and national profile

  • National Specialist Dermatopathology (NSD) EQA Scheme Steering Committee

Publications

2013

Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A,
Saldanha G, Osborne J, Hutchinson P, Tse G, Lachuer J, Puisieux A, Pringle JH,
Ansieau S, Tulchinsky E. A switch in the expression of embryonic EMT-inducers
drives the development of malignant melanoma. Cancer Cell. 2013 Oct
14;24(4):466-80. doi: 10.1016/j.ccr.2013.08.018. Epub 2013 Sep 26. PubMed PMID:
24075834.

Shaheen B, Saldanha G, Calonje E, Johnston GA. Multiple clustered
dermatofibromas (fibrous histiocytomas): an atypical clinical variant of
dermatofibroma. Clin Exp Dermatol. 2014 Jan;39(1):88-90. doi: 10.1111/ced.12200.
Epub 2013 Sep 10. PubMed PMID: 24016104.

Moore DA, Saldanha G, Ehdode A, Potter L, Dyall L, Bury D, Pringle JH.
Accurate detection of copy number changes in DNA extracted from formalin-fixed,
paraffin-embedded melanoma tissue using duplex ratio tests. J Mol Diagn. 2013
Sep;15(5):687-94. doi: 10.1016/j.jmoldx.2013.04.008. Epub 2013 Jun 27. PubMed
PMID: 23810241.

Saldanha G, Potter L, Shendge P, Osborne J, Nicholson S, Yii N, Varma S, Aslam
MI, Elshaw S, Papadogeorgakis E, Pringle JH. Plasma microRNA-21 is associated
with tumor burden in cutaneous melanoma. J Invest Dermatol. 2013
May;133(5):1381-4. doi: 10.1038/jid.2012.477. Epub 2013 Jan 10. PubMed PMID:
23303460.

2012

Moore DA, Pringle JH, Saldanha GS. Prognostic tissue markers in melanoma.
Histopathology. 2012 Apr;60(5):679-89. doi: 10.1111/j.1365-2559.2011.03910.x.
Epub 2011 Aug 22. Review. PubMed PMID: 21880059.

2011

Da Forno PD, Saldanha GS. Molecular aspects of melanoma. Clin Lab Med. 2011
Jun;31(2):331-43. doi: 10.1016/j.cll.2011.03.010. Review. PubMed PMID: 21549246.

Saldanha G, Potter L, Dyall L, Bury D, Hathiari N, Ehdode A, Hollox E, Pringle
JH. Detection of copy number changes in DNA from formalin fixed paraffin embedded
tissues using paralogue ratio tests. Anal Chem. 2011 May 1;83(9):3484-92. doi:
10.1021/ac200153j. Epub 2011 Mar 30. PubMed PMID: 21449538.

Crichlow SM, Alexandroff AB, Simpson RC, Saldanha G, Walker S, Harman KE. Is
IgA antineutrophil cytoplasmic antibody a marker for patients with erythema
elevatum diutinum? A further three cases demonstrating this association. Br J
Dermatol. 2011 Mar;164(3):675-7. doi: 10.1111/j.1365-2133.2010.10172.x. Epub 2011
Feb 3. PubMed PMID: 21143463.

2009

Da Forno PD, Pringle JH, Fletcher A, Bamford M, Su L, Potter L, Saldanha G.
BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic
significance. Br J Dermatol. 2009 Aug;161(2):364-72. doi:
10.1111/j.1365-2133.2009.09181.x. Epub 2009 Apr 29. PubMed PMID: 19438459.

2008

Da Forno PD, Pringle JH, Hutchinson P, Osborn J, Huang Q, Potter L, Hancox
RA, Fletcher A, Saldanha GS. WNT5A expression increases during melanoma
progression and correlates with outcome. Clin Cancer Res. 2008 Sep
15;14(18):5825-32. doi: 10.1158/1078-0432.CCR-07-5104. PubMed PMID: 18794093.

Da Forno PD, Fletcher A, Pringle JH, Saldanha GS. Understanding spitzoid
tumours: new insights from molecular pathology. Br J Dermatol. 2008
Jan;158(1):4-14. Epub 2007 Oct 4. Review. PubMed PMID: 17916202.

2007

Macbeth AE, Kendall BR, Smith A, Saldanha G, Harman KE. Calcified
subcutaneous nodules: a long-term complication of interferon beta-1a therapy. Br
J Dermatol. 2007 Sep;157(3):624-5. Epub 2007 Jun 26. PubMed PMID: 17596164.

2006

Saldanha G, Potter L, Daforno P, Pringle JH. Cutaneous melanoma subtypes show
different BRAF and NRAS mutation frequencies. Clin Cancer Res. 2006 Aug
1;12(15):4499-505. PubMed PMID: 16899595.

2005

Mortimer NJ, Saldanha G, Harman KE. An unusual tender eruption. Clin Exp
Dermatol. 2005 Jan;30(1):103-4. PubMed PMID: 15663524.

2004

Saldanha G, Ghura V, Potter L, Fletcher A. Nuclear beta-catenin in basal cell
carcinoma correlates with increased proliferation. Br J Dermatol. 2004
Jul;151(1):157-64. PubMed PMID: 15270885.

Research

Melanocytes, which produce pigment in skin and elsewhere, can give rise to two broad categories of tumour, malignant melanoma (a type of cancer) and benign naevi (commonly known as "moles").

Malignant melanoma is a common malignancy and often arises in relatively young adults. As a practicing histopathologist my role is to examine skin tumours that have been surgically excised under the microscope. This is important in several ways.

Firstly, to diagnose if a pigmented skin lesion is a malignant melanoma or a mole. Secondly, in the case of malignant melanoma to determine how aggressively the tumour is likely to behave (i.e. provide a prognosis). Thirdly, to identify if any further therapy may be helpful.

A treatment that has recently emerged targets a mutation in a gene called BRAF, which is found in 50% of malignant melanomas, and this can be detected in the tissue sample.

My research aims to add value to what can be gleaned already from clinical tissue samples submitted for microscopic analysis by using identifying tissue biomarkers that might improve diagnosis, give better prognosis and predict who will respond to treatment more accurately.

To support these aims, I have assembled a database of approximately 2000 melanoma tissue samples from patients diagnosed in Leicester since 2004. The tissue samples are linked to clinical features, pathological features and outcome. Crucially, this means that tissue biomarkers can be assessed in the knowledge of important clinical and histological features and follow up data.

In addition, I am assembling a collection of blood samples from individuals with malignant melanoma to analyse circulating biomarkers. The main purpose behind the collection of these samples is to identify circulating biomarkers that better predict optimal therapy for malignant melanoma patients.

My currently focus is on the analysis of circulating nucleic acids to detect the emergence of genetic resistance to therapy targeted against cancer-specific mutations.

Current grants

  • University of Leicester Proof of Concept Fund, May 2014, “Predicting melanoma treatment using circulating free DNA”, £15,000
  • CR-UK, Science Committee - Biomarker Project Award, July 2014, “A Blood Test For Melanoma - Detection and Analysis of Tumour-Derived Circulating Free DNA by Deep Sequencing (The MELSEQ Study)”, £280,000

Supervision

  • MD student: David Moore - 'Duplex ratio tests as diagnostic tissue biomarkers in malignant melanoma'

Share this page:

NEWS

Congratulations from the LCRC to Bethan Rogoyski and Aleksandra Bzura.

Bethan won best oral presentation at the AMS Midlands Academy of Medical Sciences Festival held on 27th March 2019 for her presentation on "Redeployment: The potential of repurposed drugs in preventing mesothelioma".

Aleks won the University PGR poster fair competition on 18th March 2019 for her poster entitled "New hope for treating mesothelioma cancer using PARP inhibitors".

Also, a huge well done to Grandezza Aburido who was in the semi-finals of the PGR poster fair.  

---------------------------------

Congratulations to Noura Alibrahim who passed her PhD viva recently.  Well done!

---------------------------------

In a recent exercise undertaken by the NCRI’s Clinical and Translational Radiotherapy Research Working Group (CTRad) Leicester was rated as internationally competitive/leading in the Radiation Biology Research domain, one of just four centres in the UK to achieve this rating in that domain.

---------------------------------

New: Wellcome Trust Institutional Strategic Support Fund

Details

---------------------------------

Centre Health and Wellbeing Group
Join up for a walk on the park Friday lunchtime - details here.

More information from Jenny McNair jm65@le.ac.uk

Contact Details

Leicester Cancer Research Centre
Clinical Sciences Building
University of Leicester
Leicester Royal Infirmary
Leicester LE2 7LX

T: +44 (0) 116 252 3170
E: cancerstudies@le.ac.uk

(Please note this email address should not be used for clinical referrals or patient correspondence)

Maps and Directions

Sat Nav users: 
LE1 5WW

Accessibility

AccessAble logo

The University of Leicester is committed to equal access to our facilities. DisabledGo has a detailed accessibility guide for the Robert Kilpatrick Clinical Sciences Building.

Seminars

.